Literature DB >> 23880506

Role of integrated cancer nanomedicine in overcoming drug resistance.

Arun K Iyer1, Amit Singh, Srinivas Ganta, Mansoor M Amiji.   

Abstract

Cancer remains a major killer of mankind. Failure of conventional chemotherapy has resulted in recurrence and development of virulent multi drug resistant (MDR) phenotypes adding to the complexity and diversity of this deadly disease. Apart from displaying classical physiological abnormalities and aberrant blood flow behavior, MDR cancers exhibit several distinctive features such as higher apoptotic threshold, aerobic glycolysis, regions of hypoxia, and elevated activity of drug-efflux transporters. MDR transporters play a pivotal role in protecting the cancer stem cells (CSCs) from chemotherapy. It is speculated that CSCs are instrumental in reviving tumors after the chemo and radiotherapy. In this regard, multifunctional nanoparticles that can integrate various key components such as drugs, genes, imaging agents and targeting ligands using unique delivery platforms would be more efficient in treating MDR cancers. This review presents some of the important principles involved in development of MDR and novel methods of treating cancers using multifunctional-targeted nanoparticles. Illustrative examples of nanoparticles engineered for drug/gene combination delivery and stimuli responsive nanoparticle systems for cancer therapy are also discussed.
© 2013.

Entities:  

Keywords:  1,2-distearoyl-sn-glycero 3-phosphocholine; AAc; AML; Acrylic acid; Acute myeloid leukemia; Arginine–glycine–aspartic acid; BCP; BK; Block copolymer; Bradykinin; CD; CSC; CTAB; Cancer stem cells; Cetyltrimethylammonium bromide; Chol; Cholesterol; Cyclodextrin; DDS; DLL4; DMAEMA; DOPG; DOX; DPPC; DSPC; Delta-like 4 ligand; Dex; Dexamethasone; Dioleoylphosphatidylglycerol; Dipalmitoylphosphatidylcholine; Doxorubicin; Drug delivery system; ECM; EGFR; EMT; EOEOVE; EPR; Enhanced permeability and retention; EpCAM; Epidermal growth factor receptor; Epithelial cell adhesion molecule; Epithelial–mesenchymal transition; Extracellular matrix; GILT; Gamma-interferon-inducible lysosomal thiol reductase; HDAC; HFMF; HIFU; HPMA; High intensity focused ultrasound; High-frequency magnetic field; Histone deacetylase; IARC; IPNs; Imaging; Infra-red; International agency for research on cancer; Interpenetrating networks; LCST; LTSL; Low thermosensitive liposomes; Lower critical solution temperature; MA; MAAc; MDR; MMPs; MPS; MRI; MSNP; MSNs; Magnetic resonance imaging; Maleic anhydride (MA); Matrix metalloproteinase; Mesoporous silica nanoparticles; Methacrylic acid; Mononuclear phagocytic system; Multi-drug resistance; Multifunctional nanosystems; N,N-dimethylaminoethyl methacrylate; NGF; NIR; NO; NSCLC; NTSL; Nerve growth factor; Nitric oxide; Non-small cell lung cancer; Non-thermosensitive liposomes; P-glycoprotein; P-gp; PAA; PAM; PCL; PDDA; PDEAAm; PDMAEMA; PEG; PEI; PEO; PGA; PGs; PHEA; PLGA; PNIPAAm; PSMA; PTMC; PVCL; PbAE; Poly(N,N-diethylacrylamide); Poly(N-(2-hydroxypropyl)methacrylamide); Poly(N-isopropyl acrylamide); Poly(N-vinlycaprolactam); Poly(amidoamine); Poly(caprolactone); Poly(d,l-lactide-co-glycolide); Poly(dimethyldiallylammonium chloride); Poly(ethylene glycol); Poly(ethylene oxide); Poly(glutamic acid); Poly(trimethylene carbonate); Poly(β-amino ester); Poly[2-(2-ethoxy)ethoxyethyl vinyl ether]; Poly[2-(dimethylamino)ethyl methacrylate]; Polyacrylamide; Polyethyleneimine; Prostaglandins; Prostate-specific membrane antigen; RGD; RNA interference; RNAi; SCLC; SP; SPIONs; Short hairpin RNA; Side population; Small cell lung cancer; Small interfering RNA; Superparamagnetic iron oxide nanoparticles; TF; TTSL; Targeted delivery; Tegafur; Thermosensitive liposomes; Tumor multidrug resistance; UCNPs; UCST; US; Ultrasound; Upconverting nanoparticles; Upper critical solution temperature; VEGF; VPF; Vascular endothelial growth factor; Vascular permeability factor; shRNA; siRNA; α,β-poly(N-2-hydroxyethyl)-d,l-aspartamide

Mesh:

Substances:

Year:  2013        PMID: 23880506     DOI: 10.1016/j.addr.2013.07.012

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  61 in total

1.  Expression of P2X7R in breast cancer tissue and the induction of apoptosis by the gene-specific shRNA in MCF-7 cells.

Authors:  Chao Tan; L I Han; Lili Zou; Chunhua Luo; Aihua Liu; Xiejing Sheng; Dee Xi
Journal:  Exp Ther Med       Date:  2015-08-24       Impact factor: 2.447

2.  Enhanced anti-tumor efficacy and safety with metronomic intraperitoneal chemotherapy for metastatic ovarian cancer using biodegradable nanotextile implants.

Authors:  Smrithi Padmakumar; Neha N Parayath; Shantikumar V Nair; Deepthy Menon; Mansoor M Amiji
Journal:  J Control Release       Date:  2019-05-17       Impact factor: 9.776

Review 3.  Nanoparticulate RNA delivery systems in cancer.

Authors:  Ankur Sharma; Niraj Kumar Jha; Kajal Dahiya; Vivek Kumar Singh; Kundan Chaurasiya; Aditya Narayan Jha; Saurabh Kumar Jha; Prabhu Chandra Mishra; Sunny Dholpuria; Rani Astya; Parma Nand; Amit Kumar; Janne Ruokolainen; Kavindra Kumar Kesari
Journal:  Cancer Rep (Hoboken)       Date:  2020-07-30

4.  Tumour microenvironment-responsive semiconducting polymer-based self-assembly nanotheranostics.

Authors:  Zhen Yang; Yunlu Dai; Lingling Shan; Zheyu Shen; Zhantong Wang; Bryant C Yung; Orit Jacobson; Yijing Liu; Wei Tang; Sheng Wang; Lisen Lin; Gang Niu; Pintong Huang; Xiaoyuan Chen
Journal:  Nanoscale Horiz       Date:  2018-10-18       Impact factor: 10.989

5.  A Multi-Mitochondrial Anticancer Agent that Selectively Kills Cancer Cells and Overcomes Drug Resistance.

Authors:  Yong Bo Peng; Zi Long Zhao; Teng Liu; Guo Jian Xie; Cheng Jin; Tang Gang Deng; Yang Sun; Xiong Li; Xiao Xiao Hu; Xiao Bing Zhang; Mao Ye; Wei Hong Tan
Journal:  ChemMedChem       Date:  2017-01-18       Impact factor: 3.466

Review 6.  Nanoformulations for combination or cascade anticancer therapy.

Authors:  Lei Miao; Shutao Guo; C Michael Lin; Qi Liu; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2017-06-15       Impact factor: 15.470

Review 7.  Current Advances in Black Phosphorus-Based Drug Delivery Systems for Cancer Therapy.

Authors:  Wenxin Liu; Alideertu Dong; Bing Wang; Han Zhang
Journal:  Adv Sci (Weinh)       Date:  2021-01-15       Impact factor: 16.806

Review 8.  A tumor multicomponent targeting chemoimmune drug delivery system for reprograming the tumor microenvironment and personalized cancer therapy.

Authors:  Samaresh Sau; Katyayani Tatiparti; Hashem O Alsaab; Sushil K Kashaw; Arun K Iyer
Journal:  Drug Discov Today       Date:  2018-03-15       Impact factor: 7.851

9.  Applications of nanoparticle drug delivery systems for the reversal of multidrug resistance in cancer.

Authors:  Yinghong Huang; Susan P C Cole; Tiange Cai; Y U Cai
Journal:  Oncol Lett       Date:  2016-05-17       Impact factor: 2.967

10.  Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin.

Authors:  Chaojun Xue; Changyuan Wang; Qi Liu; Qiang Meng; Huijun Sun; Xiaokui Huo; Xiaodong Ma; Zhihao Liu; Xiaochi Ma; Jinyong Peng; Kexin Liu
Journal:  Tumour Biol       Date:  2016-01-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.